Cargando…
A severe refractory COVID-19 patient responding to convalescent plasma; A case series
INTRODUCTION: Although some medicines are under research, currently, no specific antiviral drug has been approved to target 2019 novel coronavirus. In this report two severe cases of 2019 novel coronavirus disease (COVID-19) patients have been described who received convalescent plasma (CP). CASE RE...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327024/ https://www.ncbi.nlm.nih.gov/pubmed/32637086 http://dx.doi.org/10.1016/j.amsu.2020.06.018 |